{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.8","upperLimit":"92.3","value":"85.6"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.4","upperLimit":"93.6","value":"87.0"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.8","upperLimit":"91.9","value":"84.8"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"}],"units":"Participants"}],"description":"The Correct Localization Rate (CLR) will be defined as percentage of participants with a one-to-one correspondence between localization of at least one lesion identified on 18F-DCFPyL PET/CT imaging and the composite truth standard. Within 60 days following PyL PET/CT imaging, either biopsy/surgery, conventional imaging, or locoregional radiation therapy of the PyL-suspected lesion(s) will be performed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with suspected recurrence of prostate cancer and negative or equivocal findings per institutional standard of care conventional imaging were enrolled to receive a single dose of 9 mCi (333 MBq) 18F-DCFPyL injection followed by a single PET/CT scan acquired 1 to 2 hours post-dosing.","id":"OG000","title":"18F-DCFPyL Injection"}],"paramType":"NUMBER","populationDescription":"Participants who received any amount of 18F-DCFPyL and had a 18F-DCFPyL PET/CT central imaging reader result.","reportingStatus":"POSTED","timeFrame":"Within 60 days following 18F-DCFPyL PET/CT imaging.","title":"Correct Localization Rate (CLR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}